Tag: psychedelics

A Rabbi, a Minister, a Monk, and a Priest Took Magic Mushrooms. Here’s What Happened

After scientists asked “psychedelic-naïve” professional religious leaders to take psilocybin, the active ingredient in magic mushrooms, most found the experience “religiously significant, meaningful, and generally beneficial.”

Historically, several world religions incorporate psychedelic compounds in their practices. However, this is the first study to examine what impact these experiences would have on the professional work of leaders from Christianity, Islam, Judaism, and Buddhism, four of the world’s major religions.

Magic Mushrooms and Mystical Experiences

In their published study, the late Roland Griffiths, of Johns Hopkins University, and Stephen Ross and Anthony Bossis, from New York University Grossman School of Medicine, discuss the role of psychedelic compounds like LSD, psilocybin, ayahuasca, and peyote in religious ceremonies. While uses of these substances vary among cultures and religions, the researchers note that they can induce experiences that share similarities to “non-pharmacologically triggered” experiences often described as “religious, spiritual, or mystical.”

“Mystical experiences are characterized by a range of subjective features including a sense of unity, “noetic” quality (e.g., an authoritative sense of truth), transcendence of time and space, a sense of awe or sacredness, intense positive mood, transiency that nevertheless feels timeless, presence in awareness of mutually exclusive states or concepts, and ineffability,” they explain.

The researchers note that such experiences are also sometimes observed in states of consciousness “associated with near-death experiences, meditation, prayer, fasting, breathwork, and music.” Although psychedelics continue to be used in some Indigenous religious contexts, the researchers note “they are generally not used within major world religions (e.g., Hinduism, Judaism, Buddhism, Christianity, Islam).”

Curious if these religious leaders would have similar experiences and how these experiences might affect their job performance, the team recruited volunteers from all four major religions. According to the results, the study participants experienced several impacts on their personal and professional lives, including “enduring increases in well-being and spirituality,” that lasted up to 16 months after taking magic mushrooms.

Keep reading

Texas Governor Signs Bill To Create Ibogaine Research Consortium, Aiming To Develop FDA-Approved Psychedelic Drug

Texas Gov. Greg Abbott (R) has signed into law a bill to create a state-backed research consortium to conduct clinical trials on ibogaine as a possible treatment for substance use disorders and other mental health conditions. The ultimate goal of the project is to develop the psychedelic into a prescription drug with U.S. Food and Drug Administration (FDA) approval, with the state retaining a portion of the profit.

“Texas is now leading the way in the United States for the evaluation of ibogaine as a potential medication that can help improve the lives of so many Americans,” the governor said at a signing event on Wednesday. He called the psychedelic “a therapy that has shown great promise in treating” conditions such as depression, PTSD and opioid use disorder.

“I’m about to sign a law that will lead to an FDA-approved drug development clinical trial that will seek approval of ibogaine as a medication for the treatment of opioid use disorder and other behavioral health conditions, especially those suffered by our veterans,” he added. “Texas will invest $50 million to support this research, and these funds can be matched by grants and private investments.”

Under the new law, approved by the state legislature earlier this month, Texas will retain a commercial interest in “all intellectual property that may be generated over the course of the drug development clinical trials,” the legislation says, with an aim of making Texas a hub for “ibogaine-related biomedical research, development, treatment, manufacturing, and distribution.”

A quarter of revenue taken in by the state from any resulting intellectual property would fund veterans programs.

Keep reading

Nevada Lawmakers Pass Resolution Urging Congress To Reschedule Psychedelics And Expedite Research On Their Medical Benefits

The Nevada legislature has approved a joint resolution calling on Congress to reschedule certain psychedelics, streamline research and provide protections for people using the substances in compliance with state law.

After initially moving through the Senate and then the House with amendments, the Senate concurred to the other body’s changes and gave final approval to the proposal last Thursday.

SJR 10, from Sen. Rochelle Nguyen (D), has now been formally enacted and will be transmitted to President Donald Trump, Vice President JD Vance, House Speaker Mike Johnson (R) and all of the members of Nevada’s congressional delegation, as well as the heads of the Drug Enforcement Administration and National Institutes of Health.

The resolution cites research demonstrating the therapeutic potential of psychedelics in the treatment of serious mental health conditions and calls on the federal government to “reschedule psilocybin, psilocin, DMT, ibogaine, mescaline and MDMA to a schedule that better reflects the therapeutic value, low potential for abuse and safety for use under medical supervision of those compounds.”

It also points out that there have been federal developments on the issue, including the Food and Drug Administration (FDA) designation of certain psychedelics as “breakthrough therapies” and research that’s being funded to explore the substances at the Department of Defense (DOD) and U.S. Department of Veterans Affairs (VA).

The measure urges Congress to increase funding for further research, establish a “streamlined process for approving and conducting research with psychedelic compounds,” and reschedule psilocybin, psilocin, DMT, ibogaine, mescaline and MDMA under the Controlled Substances Act (CSA).

Further, it calls for the establishment of “legal protection against federal prosecution for individuals and entities complying with state law concerning the supervised adult use of psychedelic compounds and require states to enter research partnerships with the Attorney General under the Controlled Substances Act to study the public health outcomes of such state programs.”

The amendment adopted by the Assembly and now signed off on by the Senate “specifies that legal protections against federal prosecution shall be for individuals and entities who are compliant with state and local laws concerning the supervised adult use of psychedelic compounds,” Sen. James Ohrenschall (D) said on the floor.

Keep reading

Federal Judge Allows Lawsuit Seeking Home Psilocybin Care To Proceed, Rejecting Oregon Officials’ Motion To Dismiss

More people in Oregon could eventually access legal psilocybin following a new federal court ruling in favor of plaintiffs who argued that the state’s first-in-the nation psilocybin law wrongfully prevents homebound patients from seeking care.

Four care providers—three licensed psilocybin facilitators and a physician specializing in advanced and terminal illnesses—sued the state about year ago, alleging that the state Psilocybin Services Act (PSA) discriminates against disabled individuals who can’t travel to designated service centers where the substance is administered.

The providers said they were told by the Oregon Health Authority (OHA) that there was no way to accommodate homebound patients under the state’s psilocybin law.

In an 12-page ruling issued late last month, District Judge Mustafa T. Kasubhai denied the state’s motion to dismiss the suit, opining that the plaintiffs have standing to bring the challenge and that a modification of the state’s psilocybin law to provide a reasonable accommodation to homebound patients under the federal Americans with Disabilities Act (ADA) would not violate principles of federalism.

“The Court agrees with Plaintiffs and finds that their requested remedy rests on physical access rather than use or distribution of a controlled substance in violation of state and federal laws,” the ruling says. “Plaintiffs do not ask the Court to order the provision of a controlled substance, as Defendants contend. Instead…Plaintiffs seek compliance with the ADA so that their disabled clients will have the same physical access to a service that is available to nondisabled individuals.”

Reached by email on Tuesday, plaintiffs’ attorney Kathryn Tucker, said she was pleased the court ruled in favor of the providers seeking to offer home psilocybin services.

“We are eager to ensure that homebound disabled and dying Oregonians can access psilocybin services, as they are among those most likely to benefit,” she wrote. “Opening access for these Oregonians will increase demand for psilocybin produced pursuant to the PSA as well as demand for services of facilitators, particularly those with expertise in providing care to disabled persons and those with advanced illness.”

“We hope to move this forward quickly now that the court has rejected the State’s effort to dismiss, recognizing that the ADA does apply to Oregon’s psilocybin program,” she added. “Because people with advancing illness may have little time left, delay in enabling access can mean that patients who might have obtained relief from debilitating anxiety and depression will die in unrelieved suffering.”

Notably, the new opinion, noted earlier by Psychedelic Week, does not order a specific remedy. It simply allows the underlying suit, Cusker v. Oregon Health Authority, to proceed toward a final decision.

Keep reading

California Senators Kill Bill To Create Psychedelic Therapy Pilot Program For Veterans And Former First Responders

A California Senate committee has declined to advance a bipartisan bill that would have created a psilocybin pilot program for military veterans and former first responders.

After moving through two other panels with unanimous support, the measure from Sens. Josh Becker (D) and Brian Jones (R) was shelved by the Senate Appropriations Committee on Friday—with members declining to take it up or designate it as a two-year bill that could be revived later in the session.

The proposal as amended in a prior committee would have established a pilot program that would have been overseen by the University of California (UC) system. UC would have been requested to study and develop “psilocybin services” for eligible patients in up to five counties across the state in partnership with licensed clinics.

The universities would have been responsible for “protocol design, institutional review board approvals, training of psilocybin facilitators, data collection, and reporting” of the pilot program.

Under the legislation, the state would have also established a “Veterans and First Responders Research Pilot Special Fund,” with continuous appropriations to fund the work.

“Emerging research suggests that psilocybin and psilocyn, when used in a controlled setting, may offer significant benefits in treating mental health disorders, particularly those related to trauma and stress,” the bill’s findings section said.

Keep reading

Nevada Assembly Passes Resolution Urging Congress To Reschedule Psychedelics And Protect ‘Supervised Adult Use’ Of The Substances

The Nevada Assembly has amended and advanced a Senate-passed joint resolution calling on Congress to reschedule certain psychedelics, streamline research and provide protections for people using the substances in compliance with state law.

On the chamber floor on Thursday, lawmakers voted 36-6 to advance the measure—SJR 10, from Sen. Rochelle Nguyen (D)—which now returns to the Senate to consider changes made in the Assembly.

The resolution cites research demonstrating the therapeutic potential of psychedelics in the treatment of serious mental health conditions and calls on the federal government to “reschedule psilocybin, psilocin, DMT, ibogaine, mescaline and MDMA to a schedule that better reflects the therapeutic value, low potential for abuse and safety for use under medical supervision of those compounds.”

It also points out that there have been federal developments on the issue, including the Food and Drug Administration (FDA) designation of certain psychedelics as “breakthrough therapies” and research that’s being funded to explore the substances at the Department of Defense (DOD) and U.S. Department of Veterans Affairs (VA).

The measure urges Congress to increase funding for further research, establish a “streamlined process for approving and conducting research with psychedelic compounds,” and reschedule psilocybin, psilocin, DMT, ibogaine, mescaline and MDMA under the Controlled Substances Act (CSA).

Further, it calls for the establishment of “legal protection against federal prosecution for individuals and entities complying with state law concerning the supervised adult use of psychedelic compounds and require states to enter research partnerships with the Attorney General under the Controlled Substances Act to study the public health outcomes of such state programs.”

Keep reading

DEA Approves Church’s Petition To Use Psychedelics In Religious Ceremonies Without The Need For A Lawsuit

A Washington State church says the Drug Enforcement Administration (DEA) has approved its application for an exception under federal drug laws to use the psychedelic ayahuasca in religious ceremonies—and, for the first time, the agency granted the unique exemption without legal challenges.

The Church of Gaia on Friday said DEA approved a petition for congregants to use ayahuasca under the Religious Freedom Restoration Act (RFRA), which was enacted in 2009 to create a pathway for religious organizations to request a carve-out under the Controlled Substances Act (CSA).

There have been relatively few examples of DEA approving such petitions in the years since—and churches that have sought the exemption have had to engage in litigation against the federal government over their requests. Uniquely, approval for this latest petition was granted without the need for lawsuits, as Mason Marks of Psychedelic Week first reported.

“As the sacrament for the Church of Gaia, Ayahuasca serves as a profound ceremonial tool for accessing spiritual connection and abundance,” Connor Mize, founder of the church, said in a press release. “In pursuing the religious exemption, we aimed to ensure the safety of the church’s members, Indigenous elders, and leaders while protecting the right to practice our sacred ceremonies without persecution. This exemption means the church can fully embrace its religious offerings, including the Ayahuasca ceremonies we’ve long prayed for.”

Keep reading

Trump’s VA Secretary Touts Being ‘One Of The First’ In His Role To Support Psychedelic Medicine For Veterans

The head of the U.S. Department of Veteran Affairs (VA) is touting the fact that he’s “one of the first” secretaries of the agency with a commitment to exploring psychedelics as a potential therapy option for veterans.

During a pair of hearings before the House Veterans’ Affairs and Appropriations Committees on Thursday, VA Secretary Doug Collins was asked about psychedelics issues by multiple GOP lawmakers, fielding questions about his intent to facilitate research in hopes of securing access for the veteran community.

At the Veterans Affairs Committee hearing, Rep. Jack Bergman (R-MI)—co-chair of the Congressional Psychedelic Advancing Therapies (PATH) Caucus—asked whether Collins had “any visibility” about the status of VA-supported psychedelics studies.

“We’re getting there,” Collins said. “I’m also probably one of the first of the [VA] secretaries who’ve actually decided that we will take a look at it. We’re not simply putting it off, and we’re going to do everything we possibly can, under the rules given to us by Congress, to actually continue that look. What we’re seeing so far is positive.”

“What we’re seeing so far in some of the studies that are related to VA, and also outside of VA as well,” he said, “is that there has been—especially when it comes to [post-traumatic stress disorder], and also traumatic brain injury and others—we’re seeing some actual positive outcomes there, especially when it is coupled with intense counseling. And I think that’s the one of the keys that we look forward to.”

Keep reading

Texas House Approves Bill To Study Psychedelic-Assisted Therapy And Make Recommendations For Legal Access

The Texas House of Representatives on Tuesday gave initial approval on Wednesday to a bill that would establish a state-backed study into the use of psilocybin, MDMA and ketamine to treat conditions such as PTSD and depression.

Lawmakers voted 98–41 to pass HB 4014, from Rep. John Bucy III (D), on second reading. A third reading vote on final passage, expected soon, would send the measure to the Senate.

The proposal is designed to help prepare the state for what supporters see as the eventual federal approval of psychedelic-assisted therapy. In its current form, it would create a study program under the state Health and Human Services Commission, which would assess clinical trials and published literature into the efficacy of psychedelics—specifically MDMA, psilocybin and ketamine—as a treatment PTSD, depression and other mental health disorders.

Officials would also review U.S. Food and Drug Administration (FDA) actions around the therapies, evaluate treatment guidelines and make recommendations to eventually ensure legal access for Texas patients.

“This bill will prepare Texas for the safe and efficient integration of psychedelic therapies into its healthcare system,” Bucy said on the House floor, “ensuring that Texans struggling with PTSD, depression and other mental health conditions have safe, affordable access to innovative treatment upon FDA approval.”

By December 1, 2026, the commission would need to provide a report to state lawmakers with results of the study as well as “any recommendations for legislative or other action necessary to ensure patient access to psychedelic therapies for treatment of post-traumatic stress disorder, depression, and other co-occurring conditions after those therapies are approved by the United States Food and Drug Administration.”

Keep reading

Hawaii Bill To Support Psychedelic Therapy—Passed By Both Senate And House—Is Dead For The Session

A Hawaii bill to support research into psychedelic-assisted therapies that had passed both chambers of the legislature in different forms missed a legislative deadline and is now dead for the session, its sponsor tells Marijuana Moment.

SB 1042, from Sen. Chris Lee (D), was scheduled for a conference committee meeting, with lawmakers from both legislative chambers set to hammer out differences between versions of the bill passed by the House and Senate.

“Unfortunately, we ran out of time was the bottom line,” Lee said in a brief phone interview. “And that happened to a slew of bills, not just this one.”

While the proposal won’t move forward this year, the senator said the conversation this session will set the stage for a renewed effort in 2026.

“The great thing is, we had agreement on the final language in the bill,” Lee said. “So I think picking up next year from there will give us the ability to identify a clear path forward.”

Keep reading